Eli Lilly and Company (LLY)
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Eli Lilly and Novo Nordisk are spending billions to find new cardiometabolic drugs. Both companies are interested in the possibilities of genetic medicines.
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
Eli Lilly is pretty close to a $1 trillion valuation. Its lineup and pipeline will support strong growth through 2030.
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
Certain economic sectors tend to be more resilient in an uncertain macroeconomic climate. Pharmaceutical giant Eli Lilly owns a portfolio of mainstay and emerging blockbuster drugs.
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Eli Lilly's two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
Eli Lilly (LLY) closed the most recent trading day at $909.32, moving -1.65% from the previous trading session.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Eli Lilly And Co LLY is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe.
LLY, NVO & Mag 7: Stocks to Watch After Fed's Rate Cut
Steven E. Orr says people are getting healthier, and the accessibility of weight loss drugs from companies like Eli Lilly (LLY) and Novo Nordisk (NVO) make them attractive for investors. However, he warns against Mag 7 stocks, instead pointing to commodities like Gold (/GC) and Silver (/SI).
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
Why This Stock Could Be the Nvidia of Healthcare
Artificial intelligence offers not only huge opportunities in technology but also in healthcare. Novo Nordisk and Hippocratic AI are both striving to developing new pathways.
Eli Lilly's Alzheimer's treatment Kisunla wins approval in Japan
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer's is the most common form of dementia, accounting for more than 67% of cases, according to Lilly.
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment option after Eisai and Biogen's Leqembi received the nod in September last year.
